Although the involvement of FOXO4 has been investigated in tumor development as a downstream target of the PTEN/PI3K/AKT signaling pathway, few reports have discussed FOXO4 expression in HCC and its association with survival, prognosis, and drug resistance in patients with cancer. This evidence concerns the gene PIK3CG and cancer.